HRP20191585T1 - Kombinirana terapija protutijela anti cd20 s inhibitorima bcl-2 i mdm2 - Google Patents
Kombinirana terapija protutijela anti cd20 s inhibitorima bcl-2 i mdm2 Download PDFInfo
- Publication number
- HRP20191585T1 HRP20191585T1 HRP20191585T HRP20191585T1 HR P20191585 T1 HRP20191585 T1 HR P20191585T1 HR P20191585 T HRP20191585 T HR P20191585T HR P20191585 T1 HRP20191585 T1 HR P20191585T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- inhibitor
- use according
- antibody
- phenyl
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 229940083338 MDM2 inhibitor Drugs 0.000 title 1
- 239000012819 MDM2-Inhibitor Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 3
- TVTXCJFHQKSQQM-LJQIRTBHSA-N 4-[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)[C@H]1[C@H](C=2C(=C(Cl)C=CC=2)F)[C@@](C#N)(C=2C(=CC(Cl)=CC=2)F)[C@H](CC(C)(C)C)N1 TVTXCJFHQKSQQM-LJQIRTBHSA-N 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229960001183 venetoclax Drugs 0.000 claims 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1. Farmaceutski sastav, naznačen time, da sadrži kombinaciju humaniziranog protutijela B-Ly1 koje je afukozilirano količinom fukoze od 60% ili manje od ukupne količine oligosaharida na Asn297 i 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3−b]piridin-5-iloksi)benzamida (GDC-0199, ABT199) te 4-{[(2R,3S,4R,5S)-4-(4-kloro-2-fluoro-fenil)-3-(3-kloro-2-fluoro-fenil)-4-cijano-5-(2,2-dimetil-propil)-pirolidin-2-karbonil]-amino}-3-metoksi-benzojeve kiseline (RG7388) ili njegove soli, za uporabu u liječenju raka.
2. Farmaceutski sastav za primjenu prema patentnom zahtjevu 1, naznačen time, da je spomenuti rak onaj koji eksprimira CD20.
3. Farmaceutski sastav za primjenu prema patentnom zahtjevu 2, naznačen time, da je rak koji eksprimira CD20 limfom ili limfocitna leukemija.
4. Farmaceutski sastav za primjenu prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačen time, da je afukozilirano protutijelo anti-CD20 obinutuzumab.
5. Farmaceutski sastav za primjenu prema bilo kojem od patentnih zahtjeva od 1 do 4, naznačen time, da se primjenjuju jedan ili više dodatnih citotoksičnih, kemoterapijskih ili antikancerogenih agensa, ili spojevi ili ionizirajuća radijacija koji poboljšavaju efekte takvih agensa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15169199 | 2015-05-26 | ||
EP16725104.0A EP3302549B1 (en) | 2015-05-26 | 2016-05-23 | Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor |
PCT/EP2016/061517 WO2016188935A1 (en) | 2015-05-26 | 2016-05-23 | Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191585T1 true HRP20191585T1 (hr) | 2019-11-29 |
Family
ID=53264535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191585 HRP20191585T1 (hr) | 2015-05-26 | 2019-09-03 | Kombinirana terapija protutijela anti cd20 s inhibitorima bcl-2 i mdm2 |
Country Status (31)
Country | Link |
---|---|
US (1) | US20160347852A1 (hr) |
EP (1) | EP3302549B1 (hr) |
JP (1) | JP6612362B2 (hr) |
KR (1) | KR102043803B1 (hr) |
CN (1) | CN107847600B (hr) |
AR (1) | AR104735A1 (hr) |
AU (1) | AU2016267564B2 (hr) |
BR (1) | BR112017023517A2 (hr) |
CA (1) | CA2984706A1 (hr) |
CL (1) | CL2017002983A1 (hr) |
CR (1) | CR20170529A (hr) |
DK (1) | DK3302549T3 (hr) |
ES (1) | ES2744624T3 (hr) |
HK (1) | HK1252855A1 (hr) |
HR (1) | HRP20191585T1 (hr) |
HU (1) | HUE044853T2 (hr) |
IL (1) | IL255353B (hr) |
LT (1) | LT3302549T (hr) |
MA (1) | MA44645B1 (hr) |
MX (1) | MX2017014977A (hr) |
MY (1) | MY188849A (hr) |
NZ (1) | NZ736727A (hr) |
PE (1) | PE20180454A1 (hr) |
PL (1) | PL3302549T3 (hr) |
PT (1) | PT3302549T (hr) |
RS (1) | RS59204B1 (hr) |
RU (1) | RU2727196C2 (hr) |
SI (1) | SI3302549T1 (hr) |
UA (1) | UA124617C2 (hr) |
WO (1) | WO2016188935A1 (hr) |
ZA (1) | ZA201707357B (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2648476C2 (ru) | 2012-09-07 | 2018-03-26 | Дженентек, Инк. | Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2 |
CA3044526A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
EP3713607A1 (en) * | 2017-11-22 | 2020-09-30 | Nordic Nanovector ASA | Radioimmunoconjugates in combination with other drugs as treatment against nhl |
CN118084904A (zh) | 2018-01-10 | 2024-05-28 | 里科瑞尔姆Ip控股有限责任公司 | 苯甲酰胺化合物 |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
CA3092753C (en) * | 2018-07-31 | 2023-10-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab |
EP3672595B1 (en) | 2018-07-31 | 2021-07-21 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
EP3883636A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
MX2013006739A (es) * | 2010-12-16 | 2013-07-17 | Roche Glycart Ag | Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2. |
-
2016
- 2016-05-23 CR CR20170529A patent/CR20170529A/es unknown
- 2016-05-23 AU AU2016267564A patent/AU2016267564B2/en not_active Ceased
- 2016-05-23 JP JP2017561265A patent/JP6612362B2/ja active Active
- 2016-05-23 EP EP16725104.0A patent/EP3302549B1/en active Active
- 2016-05-23 BR BR112017023517-0A patent/BR112017023517A2/pt active Search and Examination
- 2016-05-23 PT PT16725104T patent/PT3302549T/pt unknown
- 2016-05-23 RS RSP20191139 patent/RS59204B1/sr unknown
- 2016-05-23 MY MYPI2017704447A patent/MY188849A/en unknown
- 2016-05-23 ES ES16725104T patent/ES2744624T3/es active Active
- 2016-05-23 HU HUE16725104 patent/HUE044853T2/hu unknown
- 2016-05-23 WO PCT/EP2016/061517 patent/WO2016188935A1/en active Application Filing
- 2016-05-23 KR KR1020177036968A patent/KR102043803B1/ko active IP Right Grant
- 2016-05-23 DK DK16725104.0T patent/DK3302549T3/da active
- 2016-05-23 CA CA2984706A patent/CA2984706A1/en active Pending
- 2016-05-23 LT LTEP16725104.0T patent/LT3302549T/lt unknown
- 2016-05-23 RU RU2017145649A patent/RU2727196C2/ru active
- 2016-05-23 CN CN201680043763.1A patent/CN107847600B/zh not_active Expired - Fee Related
- 2016-05-23 SI SI201630376T patent/SI3302549T1/sl unknown
- 2016-05-23 NZ NZ736727A patent/NZ736727A/en not_active IP Right Cessation
- 2016-05-23 MA MA44645A patent/MA44645B1/fr unknown
- 2016-05-23 MX MX2017014977A patent/MX2017014977A/es unknown
- 2016-05-23 UA UAA201712737A patent/UA124617C2/uk unknown
- 2016-05-23 PL PL16725104T patent/PL3302549T3/pl unknown
- 2016-05-23 PE PE2017002462A patent/PE20180454A1/es unknown
- 2016-05-24 AR ARP160101500A patent/AR104735A1/es unknown
- 2016-05-26 US US15/166,149 patent/US20160347852A1/en not_active Abandoned
-
2017
- 2017-10-30 ZA ZA2017/07357A patent/ZA201707357B/en unknown
- 2017-10-31 IL IL255353A patent/IL255353B/en unknown
- 2017-11-24 CL CL2017002983A patent/CL2017002983A1/es unknown
-
2018
- 2018-09-21 HK HK18112186.9A patent/HK1252855A1/zh unknown
-
2019
- 2019-09-03 HR HRP20191585 patent/HRP20191585T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191585T1 (hr) | Kombinirana terapija protutijela anti cd20 s inhibitorima bcl-2 i mdm2 | |
RU2474580C2 (ru) | Гетероциклические амидные соединения как ингибиторы протеинкиназ | |
SG11202007917VA (en) | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer | |
CY1124848T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291 | |
CL2018003290A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
SG11201907038WA (en) | Quinazoline compound | |
PH12016500372A1 (en) | Pharmaceutical composition containing pyrimidine compound as active ingredient | |
EA201791261A1 (ru) | 1,3-тиазол-2-ил замещенные бензамиды | |
HRP20150704T1 (hr) | Derivati piperidinona kao mdm2-inhibitori za lijeäśenje raka | |
SI3256109T1 (sl) | Farmacevtski sestavki, ki obsegajo N-(3,5-dimetoksifenil)-N'-(1-metiletil)-N-(3-(metil-1H-pirazol-4-il) kinoksalin-6-il)etan-1,2-diamin | |
PH12018500653A1 (en) | Salts and solid forms of monobactam antibiotic | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
BR112022008365A2 (pt) | Inibidores de cd73 | |
EP3995489A3 (en) | Disulfide compounds for delivery of pharmaceutical agents | |
JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
EA202090508A1 (ru) | Изготовление фармацевтических составов | |
AR104391A1 (es) | Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4-cianofenil)urea maleato | |
PH12020551342A1 (en) | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | |
BR112017004694A2 (pt) | composições farmacêuticas compreendendo alpelisibe | |
EA201792676A1 (ru) | Ингибиторы jak1 | |
EP4038062A4 (en) | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT | |
MX2021014918A (es) | Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6. | |
MX2016009226A (es) | Combinaciones farmaceuticas. | |
SI3655395T1 (sl) | Postopek za pripravo N-((1R,2S,SR)-5-(TERT-butilamino)-2-((S)-3-(7- TERT-butilpirazolo(1,5-A)(1,3,5)triazin-4-ilamino)-2-oksopirolidin-1-il) cikloheksil) acetamida | |
BR112018013356A2 (pt) | sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica |